|

Giredestrant Clinical Trials

8 actively recruiting trials across 4 locations

▲ +1 trial since July 2026

Also known as: GDC-9545, RG6171, RO7197597

Pipeline

Phase 1: 1Phase 2: 1Phase 3: 2Phase 1/2: 4

Top Sponsors

  • Hoffmann-La Roche3
  • Genentech, Inc.3
  • MedSIR1
  • Alliance Foundation Trials, LLC.1

Indications

  • Cancer8
  • Breast Cancer7
  • Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer1
  • Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer1
  • Metastatic Breast Cancer1

Duarte, California4 trials

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

City of Hope

Phase 1/2
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

City of Hope

Phase 1/2
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

City of Hope Comprehensive Cancer Center

Phase 1/2
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

City of Hope

Phase 1/2

Other1 trial

A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population
Phase 2

Daphne, Alabama1 trial

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Southern Cancer Center

Phase 3

Fountain Valley, California1 trial

A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)

Orange Coast Medical Center

Phase 3

Grand Rapids, Michigan1 trial

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer

START - Midwest - EDOS

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.